UNSPSC 51202406: Certolizumab pegol

This classification denotes a monoclonal antibody, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UMD07X179E. European Medicines Agency schedules Certolizumab pegol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25423.

Certolizumab pegol generally arises in the molecular formula C19H30N5O8S(C2H4O)N(C2H4O)N. The term CERTOLIZUMAB PEGOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 3, 2004, list 52.) Most nations, for tariff and trade purposes, schedule certolizumab pegol under HS 30021091 and SITC 54163. Certolizumab pegol bears US NLM identifiers UMLS ID C1872109 and NCI Concept Code C80972. SMILES: As of Q4 2014, CERTOLIZUMAB PEGOL remains US FDA's Preferred Term for this commodity.

UNSPSC 51202406 Certolizumab pegol, a Commodity code, shows minimal alignment between its nominal scope—a specific biopharmaceutical product for rheumatoid arthritis and other autoimmune conditions—and the recent state and local opportunities tagged under it. The recent solicitations captured under this code instead reflect purchases of naloxone, medical and first aid supplies for emergency response, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription program capabilities. The issuing bodies span county health departments, municipal fire services, state health and human services agencies, and multistate cooperative purchasing alliances. The mismatch between the code's specific pharmaceutical designation and the broader commodity purchases actually being solicited suggests either inconsistent internal tagging by procurement offices or that the code has been repurposed to capture general pharmaceutical procurement activity beyond its original product specification.

Recent activity appears concentrated in three states: Florida (Seminole County's naloxone and drug deactivation systems IFB, due July 26, 2023), Texas (HHS Commission's RFI on direct-to-manufacturer prescriptions, due April 3, 2026), and Minnesota (MMCAP's RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026), with the latter representing a multistate cooperative vehicle serving participating jurisdictions including Oregon. The City of Tampa issued an ITB for medical and first aid supplies for its Fire Department Rescue Division (estimated contract value $700,000.00, closed March 13, 2026, with SLBE set-aside and 5% bid discount not to exceed $10,000). No opportunities specifically soliciting certolizumab pegol or similar specialty biopharmaceuticals appear in the recent record, indicating that this code does not reflect meaningful current activity in its stated product category.